Surgical approach to locally advanced non-small cell lung cancer

Cancer Journal (United States)

Volumn 19, Issue 3, 2013, Pages 217-221

  Donington, Jessica S ^a   Pass, Harvey I ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Locally advanced disease; Multimodality therapy; Non small cell lung cancer; Thoracic surgery

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADVANCED CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOPULMONARY BYPASS; CHEMORADIOTHERAPY; HUMAN; INDUCTION CHEMOTHERAPY; LOBECTOMY; LUNG EDEMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MEDIASTINUM LYMPH NODE; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; SURGICAL MORTALITY; TRACHEA RECONSTRUCTION; TUMOR BIOPSY;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PNEUMONECTOMY; TREATMENT OUTCOME;

EID: 84880120470     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318299f647     Document Type: Review

References (44)

1. Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2:593-602.
2. Kilicgun A, Tanriverdi O, Turna A, et al. Prognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be?Med Oncol. 2012;29:607-613.
3. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med2004;350:351-360.
4. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719-727.
5. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559.
6. Alam N, Shepherd FA, Winton T, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: an analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer (Amsterdam). 2005;47:385-394.
7. Deslauriers J, Brisson J, Cartier R, et al. Carcinoma of the lung: evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg. 1989;97:504-512.
8. Yildizeli B, Dartevelle PG, Fadel E, et al. Results of primary surgery with T4 non-small cell lung cancer during a 25-year period in a single center: the benefit is worth the risk. Ann Thorac Surg. 2008;86:1065-1075; discussion 1074-1075.
9. Mitchell JD, Mathisen DJ, Wright CD, et al. Clinical experience with carinal resection. J Thorac Cardiovasc Surg. 1999;117:39-52; discussion 53.
10. de Perrot M, Fadel E, Mercier O, et al. Long-term results after carinal resection for carcinoma: does the benefit warrant the risk?J Thorac Cardiovasc Surg. 2006;131:81-89.
11. Regnard JF, Perrotin C, Giovannetti R, et al. Resection for tumors with carinal involvement: technical aspects, results, and prognostic factors. Ann Thorac Surg. 2005;80:1841-1846.
12. Jiang F, Xu L, Yuan F, et al. Carinal resection and reconstruction in surgical treatment of bronchogenic carcinoma with carinal involvement. J Thorac Oncol. 2009;4:1375-1379.
13. Burt ME, Pomerantz AH, Bains MS, et al. Results of surgical treatment of stage III lung cancer invading the mediastinum. Surg Clin North Am. 1987;67:987-1000.
14. TsuchiyaR, Asamura H, Kondo H, et al. Extended resection of the left atrium, great vessels, or both for lung cancer. Ann Thorac Surg. 1994; 57:960-965.
15. Spaggiari L, Magdeleinat P, Kondo H, et al. Results of superior vena cava resection for lung cancer: analysis of prognostic factors. Lung Cancer (Amsterdam). 2004;44:339-346.
16. Spaggiari L, Regnard JF, Magdeleinat P, et al. Extended resections for bronchogenic carcinoma invading the superior vena cava system. Ann Thorac Surg. 2000;69:233-236.
17. Spaggiari L, Tessitore A, Casiraghi M, et al. Survival after extended resection for mediastinal advanced lung cancer: lessons learned on 167 consecutive cases. Ann Thorac Surg. 2013;95:1717-1725.
18. Suzuki K, Asamura H, Watanabe S, et al. Combined resection of superior vena cava for lung carcinoma: prognostic significance of patterns of superior vena cava invasion. Ann Thorac Surg. 2004;78:1184-1189; discussion 1189.
19. Shaw RR, Paulson DL, Kee JL. Treatment of superior sulcus tumor by irradiation followed by resection. Ann Surg. 1961;154:29-40.
20. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. 2001;121:472-483.
21. Grunenwald DH, MazelC, GirardP, et al. Radical en bloc resection for lung cancer invading the spine. J Thorac Cardiovasc Surg. 2002;123:271-279.
22. Schirren J, Donges T, Melzer M, et al. En bloc resection of non-small-cell lung cancer invading the spine. Eur J Cardiothorac Surg. 2011;40:647-654.
23. Gandhi S, Walsh GL, Komaki R, et al. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann Thorac Surg. 1999;68:1778-1784; discussion 1784-1785.
24. Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg. 2008;86:362-366; discussion 366-367.
25. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981-2989.
26. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer (Amsterdam). 1998;19:3-13.
27. Casali C, Stefani A, Natali P, et al. Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg. 2005;28:33-38.
28. Veeramachaneni NK, Feins RH, Stephenson BJ, et al. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012;94:922-926; discussion 926-928.
29. Tanner NT, Gomez M, Rainwater C, et al. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. J Thorac Oncol. 2012;7:365-369.
30. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
31. Rosell R, Maestre J, Font A, et al. A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer. Semin Oncol. 1994;21:28-33.
32. Pass HI, Pogrebniak HW, SteinbergSM, et al. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992;53:992-998.
33. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clinical Oncol. 1995;13:1880-1892.
34. Fowler WC, Langer CJ, Curran WJJr, et al. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg. 1993;55:986-989.
35. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009; 374:379-386.
36. Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced nonsmall cell carcinoma of the lung. Int J Radiat Oncol. 2012;84:456-463.
37. Fernandez FG, Force SD, Pickens A, et al. Impact of laterality on early and late survival after pneumonectomy. Ann Thorac Surg. 2011;92:244-249.
38. Sonett JR, Suntharalingam M, Edelman MJ, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg. 2004;78:1200-1205; discussion 1206.
39. Daly BD, Fernando HC, Ketchedjian A, et al. Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer. Ann Thorac Surg. 2006;82:227-231.
40. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) nonsmall cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg. 2011;141:662-670.
41. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998; 352:257-263.
42. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006;24:2998-3006.
43. Sawyer TE, Bonner JA, Gould PM, et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg. 1997;64:1402-1407; discussion 1407-1408.
44. Machtay M, Lee JH, Shrager JB, et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol. 2001;19:3912-3917.